Beste Long Run With Luke Timmerman podcasts (2024)

1
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer 1:00:23

1d ago1:00:23

1:00:23

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.Door Timmerman Report

1
Ep167: Leslie Williams on transfer RNA therapies 1:11:28

20d ago1:11:28

1:11:28

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.Door Timmerman Report

1
Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity 1:03:35

1M ago1:03:35

1:03:35

Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.Door Timmerman Report

1
Ep165: Zach Hornby on Tackling Cancer Drug Resistance 1:02:45

2M ago1:02:45

1:02:45

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.Door Timmerman Report

1
Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients 56:39

3M ago56:39

56:39

Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.Door Timmerman Report

1
Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases 1:08:19

3M ago1:08:19

1:08:19

Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.Door Timmerman Report

1
Ep162: Sean McClain on AI for Biologic Drug Discovery 1:05:59

4M ago1:05:59

1:05:59

Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.Door Timmerman Report

1
Ep161: Jeff Stein on a Long-Lasting Flu Drug 1:08:51

5M ago1:08:51

1:08:51

Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.Door Timmerman Report

1
Ep160: Abe Ceesay on Precision Neuroscience 1:08:48

5M ago1:08:48

1:08:48

Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.Door Timmerman Report

1
Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease 1:07:22

6M ago1:07:22

1:07:22

Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.Door Timmerman Report

1
Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery 1:00:44

6M ago1:00:44

1:00:44

David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.Door Timmerman Report

1
Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery 56:33

7M ago56:33

56:33

Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.Door Timmerman Report

1
Ep156: David Liu on New Tools and Techniques for Biology 1:52:57

7M ago1:52:57

1:52:57

David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.Door Timmerman Report

1
Ep155: Valerie Daggett on Early Detection, and Treatment, of Alzheimer's 1:02:37

9M ago1:02:37

1:02:37

Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.Door Timmerman Report

1
Ep154: Robert Ang on CRISPR to Protect Bone Marrow & Attack Cancer 1:03:14

10M ago1:03:14

1:03:14

Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.Door Timmerman Report

1
Ep153: Rick Young on Studying Gene Expression for Drug Discovery 1:01:43

10M ago1:01:43

1:01:43

Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.Door Timmerman Report

1
Ep152: Jens Eckstein on Investing in Healthy Aging 1:05:05

11M ago1:05:05

1:05:05

Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.Door Timmerman Report

1
Ep151: Shelley Force Aldred and Nathan Trinklein on Bispecific Antibodies for Cancer 1:03:55

11M ago1:03:55

1:03:55

Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.Door Timmerman Report

1
Ep150: Jeff Jonker on the Small Molecule Drug Discovery Renaissance 1:03:48

12M ago1:03:48

1:03:48

Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.Door Timmerman Report

1
Ep149: Nancy Stagliano on Precision Neuroscience 1:01:53

12M ago1:01:53

1:01:53

Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.Door Timmerman Report

1
Ep148: Diana Brainard on the Fight Against Infectious Disease 1:03:27

1y ago1:03:27

1:03:27

Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.Door Timmerman Report

1
Ep147: Reid Huber on Investing in the Future of Medicine 1:08:41

1y ago1:08:41

1:08:41

Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.Door Timmerman Report

1
Ep146: Jeff Huber on Life in Tech and Biotech 1:47:05

1y ago1:47:05

1:47:05

Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.Door Timmerman Report

1
Ep145: Lori Lyons-Williams on Targeted Radiopharmaceuticals for Cancer 1:06:39

1y ago1:06:39

1:06:39

Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.Door Timmerman Report

1
Ep144: Turning the Tables, Rob Perez Interviews Me 1:04:58

1y ago1:04:58

1:04:58

Turning the Tables, Rob Perez Interviews MeDoor Timmerman Report

1
Ep143: Zach Weinberg and Alexis Borisy on Freeing the Biotech Founders 1:10:25

1y ago1:10:25

1:10:25

Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech FoundersDoor Timmerman Report

1
Ep142: Fred Appelbaum on how 'Living Medicine' Came to Be 55:54

1+ y ago55:54

55:54

Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.Door Timmerman Report

1
Ep141: Colin Hill on Digging Deep into Data, Finding New Drug Targets 1:09:30

1+ y ago1:09:30

1:09:30

Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.Door Timmerman Report

1
Ep140: Yung Lie on Supporting Young Scientists with Bold, Brave Ideas 1:02:40

1+ y ago1:02:40

1:02:40

Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.Door Timmerman Report

1
Ep139: Kevin Conroy on Early Detection of Cancer 1:08:28

1+ y ago1:08:28

1:08:28

Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.Door Timmerman Report

1
Ep138: Jodie Morrison on Becoming a Biotech CEO 1:00:17

1+ y ago1:00:17

1:00:17

Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.Door Timmerman Report

1
Ep137: Aaron Ring on Immunotherapy for Cancer & More 56:37

1+ y ago56:37

56:37

Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.Door Timmerman Report

1
Ep136: Deborah Palestrant on Building Biotech Startups 52:52

1+ y ago52:52

52:52

Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.Door Timmerman Report

1
Ep135: John Maraganore on Developing a New Class of Medicines 1:03:51

1+ y ago1:03:51

1:03:51

John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.Door Timmerman Report

1
Ep134: Emile Nuwaysir on In Vivo Gene Editing Therapies 1:16:22

1+ y ago1:16:22

1:16:22

Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.Door Timmerman Report

1
Ep133: Catherine Stehman-Breen on Epigenetic Editing Therapies 1:10:33

1+ y ago1:10:33

1:10:33

Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.Door Timmerman Report

1
Ep132: Eric Dobmeier on Treating Kidney Disease 1:05:44

1+ y ago1:05:44

1:05:44

Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.Door Timmerman Report

1
Ep131: Ryan Watts on Neuroscience Drug R&D 1:05:32

1+ y ago1:05:32

1:05:32

Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.Door Timmerman Report

1
Ep130: David Hallal on a Life in Biotech & the Cell Therapy Wave 1:09:29

1+ y ago1:09:29

1:09:29

David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.Door Timmerman Report

1
Ep129: Joanne Smith-Farrell on Engineered B-Cell Therapies 1:11:43

2y ago1:11:43

1:11:43

Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.Door Timmerman Report

1
Ep128: Rick Berke on Building a Biotech Journalism Outlet to Last 1:00:34

2y ago1:00:34

1:00:34

Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.Door Timmerman Report

1
Ep127: Jeb Keiper on Computational Drug Discovery 1:09:41

2y ago1:09:41

1:09:41

Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.Door Timmerman Report

1
Ep126: DA Wallach on Becoming a Biotech VC 1:11:38

2y ago1:11:38

1:11:38

DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.Door Timmerman Report

1
Ep125: Barry Greene on a New Drug for Depression 1:04:52

2y ago1:04:52

1:04:52

Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.Door Timmerman Report